# Innate Pharma (IPHA) — News

IPHA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ipha/news

## Recent headlines

- [Innate and Sobi announce partnership is now effective following completion of closing conditions](https://www.ainvest.com/news/innate-sobi-announce-partnership-effective-completion-closing-conditions-2609) — AInvest Wire, Sep 16, 2026
  Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sobi® have confirmed that their strategic partnership is now effective following the completion of all closing conditions, including necessary anti-trust clearances . Under the terms of the agreement, Sobi has paid Innate Pharma USD 75…
- [Swedish Orphan Biotriment - Innate eligible for up to $40 mln in near-term development milestones connected to Sezary syndrome](https://www.ainvest.com/news/swedish-orphan-biotriment-innate-eligible-40-mln-term-development-milestones-connected-sezary-syndrome-2608) — AInvest Wire, Aug 10, 2026
  Innate Pharma has made significant progress in its clinical development pipeline for lacutamab, an anti-KIR3DL2 antibody targeting Sézary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma (CTCL). The company is currently preparing for the initiation of the TELLOMAK-3 Phase 3 trial…
- [Sobi will pay Innate Pharma $75M](https://www.ainvest.com/news/sobi-pay-innate-pharma-75m-2608) — AInvest Wire, Aug 10, 2026
- [Innate Pharma - preliminary data from 76 patients expected by year-end](https://www.ainvest.com/news/innate-pharma-preliminary-data-76-patients-expected-year-2607) — AInvest Wire, Jul 21, 2026
- [Innate Pharma - IPH4502 shows favorable safety profile with hematological toxicity to date](https://www.ainvest.com/news/innate-pharma-iph4502-shows-favorable-safety-profile-hematological-toxicity-date-2607) — AInvest Wire, Jul 21, 2026
  Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has reported that its investigational Antibody Drug Conjugate (ADC), IPH4502, has demonstrated a favorable safety profile in early clinical trials, with primary observed adverse event . The drug is currently being evaluated in a Phase 1 trial…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).